We showed previously that amino acid (aa) substitutions in hepatitis C virus core region (HCV-CR) are negative predictors of virologic response to pegylated interferon (IFN) plus ribavirin therapy. HCV-CR induces hepatocellular carcinoma in transgenic mice, but the clinical impact is still unclear.
Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus
✍ Scribed by Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 113 KB
- Volume
- 81
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Previous studies provided a direct experimental evidence for the contribution of HCV core protein in the development of insulin resistance (IR), but the clinical impact of HCV core region on IR is still not clear. The present study evaluated the impact of Amino acid (aa) substitutions of HCV‐1b core region on IR in 123 Japanese patients infected with HCV‐1b without cirrhosis and diabetes mellitus, and investigated the treatment efficacy of 48‐week pegylated interferon (PEG‐IFN) plus ribavirin (RBV) according to HOMA‐IR values. Patients with IR (HOMA‐IR ≥2.5) and severe IR (HOMA‐IR ≥3.5) were present in 51.2% and 27.6%, respectively. Multivariate analysis identified body mass index (≥25 kg/m^2^) and hepatocyte steatosis (≥5%) as significant determinants of IR. Furthermore, multivariate analysis identified hepatocyte steatosis (≥5%), aa substitutions of the core region (Gln70 (His70) and/or Met91), and age (≥55 years) as significant determinants of severe IR. Especially, significantly lower proportions of patients with Gln70 (His70) and/or Met91 were noted among those without severe IR (59.6%) than those with severe IR (82.4%). The rates of sustained virological response in patients with IR (50.0%) were not significantly different from those without IR (52.9%). Furthermore, the rates of non‐virological response in patients with IR (28.9%) were not significantly also different from those without IR (20.6%). In conclusion, the present study indicated that substitutions of HCV‐1b core region were the important predictor of severe IR in patients without cirrhosis and diabetes mellitus, but HOMA‐IR values might be not useful as predictors of 48‐week PEG‐IFN plus RBV therapy. J. Med. Virol. 81:1032–1039, 2009. © 2009 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Previous studies identified amino acid (aa) substitutions of the hepatitis C virus core region of genotype 1b (HCV‐1b core region) and elevated serum alpha‐fetoprotein (AFP) levels as predictors of poor virologic response to pegylated interferon (PEG‐IFN) plus ribavirin (RBV), and also
## Abstract It has been reported that genetic polymorphisms near the __IL28B__ gene or amino acid substitutions in hepatitis C virus (HCV) core protein are associated with the clinical outcome of peginterferon (PEG‐IFN) and ribavirin combination therapy. The impact of these factors on the pure sens
## Abstract Substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG‐IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG‐IFN/ribavirin is not clear. The aims of this s
biochemical and histological improvement. 3,4 Several factors Hepatitis C virus (HCV) genotype 1b and high precan predict a poor response to interferon therapy, e.g., high treatment virus load are predictive factors of poor repretreatment virus load, genotype 1b, advanced histological sponse to inte
The substitution of amino acid (aa) 70 of arginine for glutamine and/or that of aa91 of leucine for methionine in the core protein in patients infected with hepatitis C virus (HCV) genotype 1b is associated with a poor response to pegylated interferon and ribavirin. Factors influencing these substit